NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$12.43

21 Nov
2024

-1.260

OPEN

$13.58

-9.20%

HIGH

$13.68

1,147,833

LOW

$12.42

TARGET
$25.00 101.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 123.6 108.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% - 12.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 11.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx123.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx231.9 M
Book Value Per Share xxxxxxxxxxxxxxx161.2
Net Operating Cash Flow xxxxxxxxxxxxxxx184.9 M
Net Profit Margin xxxxxxxxxxxxxxx67.73 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx127.30 %
Return on Invested Capital xxxxxxxxxxxxxxx127.30 %
Return on Assets xxxxxxxxxxxxxxx107.87 %
Return on Equity xxxxxxxxxxxxxxx127.30 %
Return on Total Capital xxxxxxxxxxxxxxx161.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx184.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx229 M
Price To Book Value xxxxxxxxxxxxxxx15.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.02 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

12/11/2024

1

Buy

$25.00

101.13%

Bell Potter assesses a positive update by Acadia Pharmaceuticals (the commercial partner for Neuren Pharmaceuticals' Daybue product), with management expressing confidence in further Daybue sales and volume growth in 2025.

The broker forecasts the company will have more than $350m in cash as of 1Q 2025 after receiving two cash milestone payments early next year of around $76m each.

The $25 target is unchanged. Buy rating remains.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 108.60 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

12/11/2024

1

Buy

$29.00

133.31%

Canaccord Genuity points to Neuren Pharmaceuticals' royalty income from Daybue sales for Rett syndrome reached $13.2m in 3Q2024, contributing to $37.5m year-to-date.

The broker highlights 2024 revenue guidance for Daybue, managed by Acadia Pharmaceuticals, has been narrowed to the lower end. The analyst believe this is a positive for the company.

A sales milestone of US$50m was triggered, alongside an expected US$50m from the sale of Acadia’s priority review voucher.

Canaccord Genuity emphasises Neuren Pharmaceuticals is valued primarily on Daybue, with upside potential tied to its NNZ-2591 pipeline asset, targeted for Phase III in Phelan-McDermid syndrome.

No change to Buy rating and $29 target.

FORECAST
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 58.00 cents.
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 88.00 cents.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Nov 12, 2024

Nov 12 2024 - Daily Market Reports
4
Next Week At A Glance – 11-15 Nov 2024

Nov 08 2024 - Weekly Reports
5
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps